Eloxx Pharmaceuticals, Inc. - FORM 10-K - EX-32.1 - EXHIBIT 32.1 - September 29, 2014

Attached files

file filename
EX-10.7 - EXHIBIT 10.7 - Eloxx Pharmaceuticals, Inc.v388379_ex10-7.htm
EXCEL - IDEA: XBRL DOCUMENT - Eloxx Pharmaceuticals, Inc.Financial_Report.xls
EX-23.1 - EXHIBIT 23.1 - Eloxx Pharmaceuticals, Inc.v388379_ex23-1.htm
EX-21.1 - EXHIBIT 21.1 - Eloxx Pharmaceuticals, Inc.v388379_ex21-1.htm
EX-10.14 - EXHIBIT 10.14 - Eloxx Pharmaceuticals, Inc.v388379_ex10-14.htm
EX-31.1 - EXHIBIT 31.1 - Eloxx Pharmaceuticals, Inc.v388379_ex31-1.htm
EX-32.2 - EXHIBIT 32.2 - Eloxx Pharmaceuticals, Inc.v388379_ex32-2.htm
EX-10.12 - EXHIBIT 10.12 - Eloxx Pharmaceuticals, Inc.v388379_ex10-12.htm
EX-31.2 - EXHIBIT 31.2 - Eloxx Pharmaceuticals, Inc.v388379_ex31-2.htm
EX-10.18 - EXHIBIT 10.18 - Eloxx Pharmaceuticals, Inc.v388379_ex10-18.htm
10-K - 10-K - Eloxx Pharmaceuticals, Inc.v388379_10k.htm
EX-10.9 - EXHIBIT 10.9 - Eloxx Pharmaceuticals, Inc.v388379_ex10-9.htm
EX-10.13 - EXHIBIT 10.13 - Eloxx Pharmaceuticals, Inc.v388379_ex10-13.htm
EX-10.28 - EXHIBIT 10.28 - Eloxx Pharmaceuticals, Inc.v388379_ex10-28.htm
EX-10.6 - EXHIBIT 10.6 - Eloxx Pharmaceuticals, Inc.v388379_ex10-6.htm
EX-10.44 - EXHIBIT 10.44 - Eloxx Pharmaceuticals, Inc.v388379_ex10-44.htm
EX-10.10 - EXHIBIT 10.10 - Eloxx Pharmaceuticals, Inc.v388379_ex10-10.htm
EX-10.26 - EXHIBIT 10.26 - Eloxx Pharmaceuticals, Inc.v388379_ex10-26.htm
EX-10.11 - EXHIBIT 10.11 - Eloxx Pharmaceuticals, Inc.v388379_ex10-11.htm
EX-10.8 - EXHIBIT 10.8 - Eloxx Pharmaceuticals, Inc.v388379_ex10-8.htm

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

 

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report on Form 10-K of Senesco Technologies, Inc. for the year ended June 30, 2014 as filed with the Securities and Exchange Commission on the date hereof, the undersigned, Ronald Martell, Chief Executive Officer, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

(1)          The Annual Report fully complies with the requirements of Section 13(a) or 15(d)

of the Securities Exchange Act of 1934; and

(2)          The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of Senesco Technologies, Inc.

 

Dated: September 29, 2014 /s/ Ronald Martell *
  Ronald Martell
  President and Chief Executive Officer
  (principal executive officer)

 

*  A signed original of this written statement required by Section 906 has been provided to us and will be retained by us and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

Eloxx Pharmaceuticals, Inc. Reports